AP NEWS

Cervical Cancer Market Spotlight 2018-2028 - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Market Spotlight: Cervical Cancer” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The author estimates that in 2016, there were 556,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 609,500 incident cases by 2025. Incidence cases are highest in Asia, and lowest in the Oceania region. Roche’s Avastin (bevacizumab) and Amgen’s Mvasi (bevacizumab), which target vascular endothelial growth factor; Novartis’s Hycamtin (topotecan hydrochloride), a topoisomerase I inhibitor; and Pinnacle’s Photofrin (porfmer sodium), a photodynamic therapy, are the only marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route. Therapies in mid-to-late-stage development for cervical cancer focus on a variety of targets. The majority of the drugs in mid-to-late-stage development for cervical cancer are administered via the intravenous route, with the remainder being intramuscular, intranasal, subcutaneous, and oral. High-impact upcoming events for drugs in the cervical cancer space include topline Phase II and Phase III trial results. Licensing and asset acquisition activity involving cervical cancer drugs has been weak during 2012-17, with only 11 deals over this time period. The $727.5m license agreement between Inovio and MedImmune for the exclusive rights to develop and market Inovio’s INO-3112 was the largest deal during 2012-17. The clinical trials distribution across Phase I-IV indicates that the majority of trials for cervical cancer have been in early and midphases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV. The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia. Clinical trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca and Roche have the highest number of ongoing clinical trials for cervical cancer, with 11 and eight ongoing trials, respectively. AstraZeneca leads industry sponsors with the highest number of clinical trials for cervical cancer, followed by Roche.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Surgery

Radiotherapy

Chemotherapy

Targeted therapy

EPIDEMIOLOGY

MARKETED DRUGS

Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

LICENSING AND ASSET ACQUISITION DEALS

Alligator And Aptevo Seal Immuno-Oncology Pact

Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY

Prescription Information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/txfq5r/cervical_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006280/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cervical Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: WOMEN HEALTH CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL CONSUMER

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 03:23 PM/DISC: 05/14/2018 03:23 PM

http://www.businesswire.com/news/home/20180514006280/en

AP RADIO
Update hourly